Board of Directors

Ehud Marom – Chairman of the Board

Mr. Marom serves as Chairman of the board at PharmaTwoB. In addition, Mr. Marom is Chairman of the board & CEO at Stem Cell Medicine and Mapi Pharma.
He brings vast experience in management, operations, business and strategic planning in the pharmaceutical industry, where he held the positions over the years. Past positions include VP of Operations at Teva Pharmaceuticals’ API and Innovative divisions, where he was credited for his contribution to the market success of Teva; COO of Peptor Ltd; CEO of the Jerusalem-based biotechnology company, Gamida Cell, a leader in hematopoietic (blood) stem cell therapeutics; President and CEO of Makhteshim Chemical Works Ltd., followed by position of Senior VP of Supply Chain at Makhteshim-Agan Group.
Mr. Marom holds B.Sc. with distinction in Chemical Engineering from the Technion – Israel Institute of Technology.

Jeff Kindler 

Mr. Kindler is Chief Executive Officer of Centrexion Therapeutics; Executive Chairman of vTv Therapeutics; a Venture Partner at Lux Capital; Global Chair of the GLG Institute; and a Managing Director at Starboard Capital Partners. Mr. Kindler serves on the boards of a number of publicly and privately held health care companies as well as several not-for-profit institutions. From 2006 to 2010, Mr. Kindler was the Chairman and Chief Executive Officer of Pfizer Inc. Prior to his appointment as Pfizer’s CEO, Mr. Kindler served as Pfizer’s Executive Vice President and General Counsel as well as a Vice Chairman of the company.Prior to joining Pfizer in 2002, he was Chairman of Boston Market Corporation from 2000 to 2001 and President of the Partner Brands group of McDonalds Corporation during 2001. Mr. Kindler holds a bachelor’s degree from Tufts University Summa Cum Laude and a J.D. from Harvard Law School Summa Cum Laude.

Maya Liquornik

Mrs. Liquornik is a senior Partner at ‎Meitar Liquornik Geva Leshem Tal – Israel’s leading international law firm. Mrs. Liquornik represents corporations in a broad range of international and domestic corporate and commercial transactions, with emphasis on mergers and acquisitions, private equity financings, venture capital, information and communications technology transactions, outsourcing and advisory work. Maya has substantial experience in structuring and negotiating complex cross border technology and outsourcing transactions. Maya’s practice focuses on representing large publicly traded corporations, technology companies in various stages of development, venture capital and private equity funds and other corporate and investment banking clients. Prior to joining Meitar, Maya was an associate at Weil, Gotshal & Manges in New York. Mrs. Liquornik holds B.A.and LL.B. with Honors, from Tel Aviv University, Israel.

Itamar Borowitz

Dr. Itamar Borowitz is Managing Partner of Crossroad VC, the high-tech investment arm of the Generali Insurance Group in Israel and Chairman of the China Israel Innovation Center in Futain District, Shenzhen, China. Dr. Borowitz is the Chairman of Yissum, the Technology Transfer Company of The Hebrew University of Jerusalem. He is a member of the Advisory Board of GLL Real Estate Partners GmBH. In the years 1992-2001 Dr. Borowitz was the CEO of the Phoenix Insurance Group, the Israel’s second largest insurance company, and in the years 1998-2001 the Chairman of the Israeli Insurance Association. Dr. Borowitz is a member of the Board of Governors of the of Tel Aviv University and member of the Board of Governors of the Hebrew University in Jerusalem, where he also serves as  a member of the Funds Committee and of the Investment Committee. Dr. Borowitz holds a PhD in Physics, and an MBA and a B.A. in General History from Tel Aviv University

Tomer Berkovitz

Dr. Tomer Berkovitz is a Managing Director & CFO at aMoon and has more than a decade of US capital markets experience. Prior to joining aMoon, he was the CFO & COO of Alcobra (NASDAQ: ADHD), a development-stage biotech company, where he led two successful public equity offerings from leading US healthcare funds and led Alcobra’s merger with Arcturus Therapeutics (NASDAQ: ARCT), a San-Diego based mRNA company.
Prior to joining Alcobra, he was an Executive Director in J.P. Morgan’s Investment Banking Division in New York, Citigroup’s Investment Bank in New York, and served as an economist in the Financial Advisory Unit to the Chief of Staff of the Israel Defense Forces. Dr. Berkovitz holds a Ph.D. in Finance and Economics (with Distinction) from Columbia Business School and holds an M.Sc. in Finance and Accounting and a B.A. in Economics and Management from Tel-Aviv University.

David Jonas

Mr. Jonas is the founder, president and Chief Executive Officer of JVC Investment Partners LLC, a firm that provides private investment and strategic support in the healthcare space. Mr. Jonas founded PharMEDium Healthcare Corporation (industry’s leader and preeminent provider of hospital sterile compounding services for IV and Epidural therapies, a $10 billion market in the USA.)and was its Chairman and Chief Executive Officer. Prior to founding JVC Investment Partners and PharMEDium, Mr. Jonas held  a number of senior management  position with Baxter including its co-founder of  Renal Therapy Services Worldwide Inc. He serves and served on a number of privately held companies and not for profit organizations. Mr. Jonas holds B.Sc and MBA from Roosevelt University, Chicago Illinois.

David Kronfeld

Mr. Kronfeld is the Chairman of JK&B Capital, L.L.C., a venture capital firm, which he founded in 1995. Prior thereto he served as a General Partner at Boston Capital Ventures, the Vice President of Acquisitions and Venture Investments at Ameritech, a Senior Manager at Booz Allen & Hamilton and a Systems Analyst at Electronic Data Systems.  Since February 2010, Mr. Kronfeld has been a director, and a member of the compensation committee, of Dynasil Corporation of America (NASDAQ-GM:DYSL). Mr.Kronfeld holds MS in Computer Science from Stevens Institute of Technology and MBA from Wharton Business School.

We at PharmaTwoB are
striving to make your
life better by developing
innovative, products
based on previously
approved drugs.